Vianex S.A.

Vianex S.A. is a Greek pharmaceutical company headquartered in Athens. Its activities span the manufacture, import, packaging, marketing, and distribution of medicines and healthcare products across a broad range of therapeutic categories. The company operates as a diversified pharmaceutical platform rather than as a single-product consumer brand: its portfolio includes prescription medicines, over-the-counter products, vaccines, antibiotics, blood-derived products, nutritional products, diagnostics, and specialized cosmetic and dermatological offerings. The company belongs to the Giannakopoulos family's long involvement in pharmaceuticals. That history is traced to 1924, when Dimitrios Giannakopoulos established a pharmacy in Athens. In 1960, Pavlos Giannakopoulos founded Pharmagian, a business that represented international pharmaceutical companies in Greece. The enterprise was reorganized as a société anonyme in 1971 and adopted the Vianex name. Manufacturing began in 1977 with the establishment of its first plant in the Athens area, marking a transition from pharmaceutical representation and distribution toward industrial production. Vianex expanded its manufacturing base during the 1980s and 1990s. It obtained a plant in Pallini, in the Athens region, from Winthrop-Sterling in 1983 and added another facility in 1985. In 1995, the growth of the over-the-counter sector led to the creation of Vian S.A., intended to distribute OTC pharmaceutical and non-pharmaceutical products. A fourth plant was established in the industrial area of Patras in 1999, with a focus on selected antibiotic products. The company therefore developed a geographically distributed Greek production footprint consisting of three factories in the Attica region and another in Patras. Vianex's commercial and industrial scope is supported by relationships with major international pharmaceutical companies. Partnerships and alliances have included Merck & Co. of the United States, Sanofi Pasteur MSD of France, and Takeda Pharmaceutical Company of Japan. These relationships reflect the company's role in local production, distribution, and commercialization as well as its own product activities. Vianex has also exported registered products for more than two decades to markets in Europe, the Middle East, Africa, and Asia. Its export network has included countries such as the United Kingdom, France, Germany, Cyprus, Jordan, Saudi Arabia, Tunisia, South Africa, the Philippines, Japan, Vietnam, Singapore, and Taiwan. Research and development became a more explicit part of the organization in 2006, when Vianex established ELDRUG S.A. as an R&D spin-off. ELDRUG's work was based on research findings and technical expertise associated with the University of Patras. Vianex has also described cooperation with universities on new pharmaceutical formulations and active molecules aimed at serious diseases. In 2011, the company became an approved supplier of the World Health Organization, an indication that its manufacturing and supply activities had met the relevant procurement requirements at that time. In 2019, Vianex acquired the Greek pharmaceutical company Pharmanel, extending its domestic pharmaceutical activities. Overall, Vianex combines domestic manufacturing infrastructure, international partnerships, export operations, OTC distribution, and pharmaceutical research. Its positioning is that of a broad-based Greek pharmaceutical manufacturer and healthcare company with capabilities covering the product lifecycle from development and production through packaging, marketing, distribution, and international supply.

Vianex's corporate history is rooted in a Greek family pharmaceutical tradition that predates the company's formal incorporation. In 1924, Dimitrios Giannakopoulos opened a pharmacy on Peiraios Street in Athens. This business provided the foundation for several decades of family involvement in medicines and pharmaceutical commerce. In 1960, his son Pavlos Giannakopoulos founded Pharmagian, which represented major international pharmaceutical companies in the Greek market. The business adopted the Vianex name in 1971 when it became a société anonyme. At that stage, the company was positioned to develop beyond representation and trading into broader pharmaceutical operations. It entered manufacturing in 1977 by establishing its first production plant in the Athens area. This move gave Vianex an industrial base and allowed it to participate more directly in the production and supply of medicines. The manufacturing network expanded during the following decade. In 1983, Vianex obtained a second plant in Pallini, in the Athens region, from Winthrop-Sterling. A third plant was added in 1985. The company subsequently broadened its distribution activities as the Greek OTC market developed. In 1995, it founded Vian S.A. to distribute over-the-counter pharmaceutical and non-pharmaceutical products, creating a dedicated structure for consumer-facing healthcare categories. Vianex added a fourth production facility in 1999 in the industrial area of Patras. The Patras plant focused on the manufacture of certain antibiotics, complementing the company's three facilities in Attica. The resulting network established Vianex as a Greek manufacturer with capabilities distributed across several production sites rather than as a business dependent solely on imports or third-party representation. During this period, Vianex also developed relationships with international pharmaceutical groups. Its strategic partnerships and alliances included Merck & Co., Sanofi Pasteur MSD, and Takeda Pharmaceutical Company Limited. These relationships supported the company's participation in international pharmaceutical supply and commercial activities. Vianex exported registered products for more than twenty years to countries across Europe, the Middle East, Africa, and Asia, including markets such as the United Kingdom, France, Germany, Cyprus, Jordan, Saudi Arabia, Tunisia, South Africa, Japan, Vietnam, Singapore, and Taiwan. Research and development became a distinct organizational priority in 2006, when Vianex created ELDRUG S.A. as an R&D spin-off. The spin-off based its work on research and technical capabilities linked to the University of Patras. Vianex has also pursued cooperation with universities on pharmaceutical formulations and active molecules intended for the treatment of serious diseases. This research activity complemented the company's established manufacturing, packaging, marketing, and distribution functions. In 2011, Vianex became an approved supplier of the World Health Organization. The approval added an international institutional dimension to its supply activities. In 2019, Vianex acquired Pharmanel, a Greek pharmaceutical company, continuing its expansion within the domestic pharmaceutical sector. Vianex's historical development can therefore be understood in four stages: family pharmacy and pharmaceutical representation; incorporation and domestic manufacturing; expansion into multiple plants, OTC distribution, and international partnerships; and the addition of research capabilities and acquisitions. The company ultimately developed into an integrated Greek pharmaceutical organization with production, distribution, export, and R&D activities.

• 2019

  Pharmanel acquisition

  [1]Vianex S.A.en.wikipedia.org

  Vianex acquired the Greek pharmaceutical company Pharmanel.

• 2011

  WHO supplier approval

  [1]Vianex S.A.en.wikipedia.org

  Vianex became an approved supplier of the World Health Organization.

• 2006

  ELDRUG R&D spin-off is established

  [1]Vianex S.A.en.wikipedia.org

  Vianex created ELDRUG S.A. to conduct pharmaceutical research connected with the University of Patras.

• 1999

  Patras manufacturing plant opens

  [1]Vianex S.A.en.wikipedia.org

  A fourth plant was added in Patras, focusing on the manufacture of selected antibiotics.

• 1995

  Vian S.A. is established

  [1]Vianex S.A.en.wikipedia.org

  Vianex founded Vian S.A. to distribute OTC pharmaceutical and non-pharmaceutical products.

• 1985

  Third plant added

  [1]Vianex S.A.en.wikipedia.org

  The company expanded its manufacturing footprint with a third facility.

• 1983

  Pallini plant acquired

  [1]Vianex S.A.en.wikipedia.org

  Vianex obtained a second plant in Pallini from Winthrop-Sterling.

• 1977

  First manufacturing plant opens

  [1]Vianex S.A.en.wikipedia.org

  Vianex began manufacturing operations with its first plant in the Athens area.

• 1971

  The company adopts the Vianex name

  [1]Vianex S.A.en.wikipedia.org

  The business became a société anonyme and changed its name to Vianex.

• 1960

  Pharmagian is founded

  [1]Vianex S.A.en.wikipedia.org

  Pavlos Giannakopoulos founded Pharmagian to represent major international pharmaceutical companies in Greece.

• 1924

  Family pharmaceutical activity begins in Athens

  [1]Vianex S.A.en.wikipedia.org

  Dimitrios Giannakopoulos opened a pharmacy in Athens, establishing the family history in the pharmaceutical field that later supported the creation of Vianex.

A diversified Greek pharmaceutical manufacturer and healthcare company serving domestic and international markets through production, pharmaceutical partnerships, distribution, exports, and research and development.

• Pharmaceuticals

  Prescription medicines

  Prescription medicines form the core of Vianex's regulated pharmaceutical portfolio. The company's activities cover multiple therapeutic fields, including gastroenterology, oncology, neurology, psychiatry, urology, hypertension, cholesterol management, dermatology, and osteoporosis. The portfolio is supported by manufacturing, importing, packaging, marketing, and distribution capabilities rather than being limited to a single therapeutic specialty.

• Pharmaceuticals

  Hospital and specialist medicines

  Vianex's specialist and clinical supply activities include antibiotics, vaccines, systemic anti-inflammatory products, blood-derived products, and treatments associated with asthma and ophthalmic care. These products reflect the company's role in supplying both general pharmaceutical channels and more specialized healthcare settings.

• Consumer healthcare · 1995

  Over-the-counter medicines

  The OTC portfolio includes non-prescription medicines, particularly general analgesics and topical or systemic antiseptics. Distribution of these products was a principal reason for establishing Vian S.A. in 1995, giving Vianex a dedicated route into consumer healthcare and non-prescription pharmaceutical markets.

• Nutrition

  Nutritional and infant nutrition products

  Vianex's non-pharmaceutical activities include nutritional supplements and infant nutrition formulations. These products broaden the company's healthcare offering beyond medicines and address dietary and nutritional needs through consumer and family-health channels.

• Diagnostics and personal care

  Diagnostics and specialized skincare

  The company also operates in medical diagnostics and markets cosmetics focused on specialized skincare and dermatological hygiene. These categories extend Vianex's business into adjacent healthcare and personal-care segments while remaining connected to its pharmaceutical and dermatological expertise.

• 2019

  Acquisition of PharmanelM&A

  Background

  Vianex continued expanding its presence in the Greek pharmaceutical sector.

  Action taken

  Vianex acquired Pharmanel, a Greek pharmaceutical company.

  Aftermath

  The transaction broadened Vianex's domestic corporate and pharmaceutical activities.

  Source

• 2006

  Establishment of ELDRUG research spin-offStrategy

  Background

  Vianex sought to expand beyond manufacturing and distribution into pharmaceutical research and formulation development.

  Action taken

  It established ELDRUG S.A. as an R&D spin-off linked to the research findings and technical expertise of the University of Patras.

  Aftermath

  The company added a formal research vehicle and continued university cooperation on formulations and active molecules.

  Source

• 1995

  Creation of Vian S.A. for OTC distributionStrategy

  Background

  Growth in over-the-counter medicines and non-pharmaceutical healthcare products created a need for a dedicated distribution structure.

  Action taken

  Vianex founded Vian S.A. to distribute OTC pharmaceutical and non-pharmaceutical products.

  Aftermath

  The organization gained a separate platform for consumer healthcare distribution alongside its prescription and manufacturing activities.

  Source

• 1977

  Move into pharmaceutical manufacturingStrategy

  Background

  After operating in pharmaceutical representation and commerce, Vianex sought to develop its own industrial production capability.

  Action taken

  The company established its first manufacturing plant in the Athens area.

  Aftermath

  The move began Vianex's transition into an integrated pharmaceutical manufacturer and preceded later expansion to four plants.

  Source

• 2019

  Vianex acquires Pharmanel[1]Vianex S.A.en.wikipedia.org

  M&A

  Vianex acquired the Greek pharmaceutical company Pharmanel as part of the expansion of its domestic pharmaceutical activities.

• 2011

  Vianex becomes an approved World Health Organization supplier[1]Vianex S.A.en.wikipedia.org

  Other

  Vianex became an approved supplier for the World Health Organization, strengthening its institutional and international supply credentials.

• 2006

  Vianex establishes an R&D spin-off, ELDRUG S.A.[1]Vianex S.A.en.wikipedia.org

  Other

  Vianex established ELDRUG S.A. to pursue pharmaceutical research drawing on findings and technical expertise associated with the University of Patras.

1. 1Vianex S.A.en.wikipedia.org